Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real‐world clinical experience from India

Abstract

Close monitoring of patients receiving biologics is essential for early identification of adverse events, especially in test negative patients. Prophylaxis can effectively reduce the risk of developing TB in patients positive for screening.